2024
Speech motion anomaly detection via cross-modal translation of 4D motion fields from tagged MRI
Liu X, Xing F, Zhuo J, Stone M, Prince J, El Fakhri G, Woo J. Speech motion anomaly detection via cross-modal translation of 4D motion fields from tagged MRI. Proceedings Of SPIE--the International Society For Optical Engineering 2024, 12926: 129262w-129262w-5. PMID: 39238547, PMCID: PMC11377028, DOI: 10.1117/12.3006874.Peer-Reviewed Original ResearchCross-modal translationHealthy individualsTongue cancer patientsMotion fieldOut-of-distributionOne-class SVMPatient dataAnomaly detectionAnomaly detectorCancer patientsTagged MRISpeech-related disordersGeneralization capabilityReconstruction qualitySpeech qualityArticulatory-acoustic relationsPatientsSpeech waveformTraining setInnovative treatmentsMRITest setMotion patternsArticulatory featuresTraining translators
2017
Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib
Collier T, Normandin M, Stephenson N, Livni E, Liang S, Wooten D, Esfahani S, Stabin M, Mahmood U, Chen J, Wang W, Maresca K, Waterhouse R, El Fakhri G, Richardson P, Vasdev N. Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib. Nature Communications 2017, 8: 15761. PMID: 28594000, PMCID: PMC5472746, DOI: 10.1038/ncomms15761.Peer-Reviewed Original ResearchMeSH KeywordsAminopyridinesAnaplastic Lymphoma KinaseAnimalsCarbon RadioisotopesChemistry Techniques, SyntheticContrast MediaFluorine RadioisotopesHumansIsotope LabelingLactamsLactams, MacrocyclicMacaca mulattaMaleMicePositron-Emission TomographyProtein-Tyrosine KinasesProto-Oncogene ProteinsPyrazolesTissue DistributionXenograft Model Antitumor AssaysConceptsAnaplastic lymphoma kinasePositron emission tomographyPositron emission tomography imagingC-ros oncogene 1Non-small cell lung cancerCell lung cancerBrain tumor lesionsOptimal therapeutic outcomesLung cancer patientsBlood-brain barrierPF-06463922Clinical trial investigatorsTumor uptakeLung cancerSmall molecule inhibitorsCancer patientsTherapeutic outcomesLorlatinibEmission tomographyDosimetry assessmentNon-human primatesTrial investigatorsBrain permeabilityEarly goalRadiolabeling strategies